JP Morgan Chase
MNPR icon

JP Morgan Chase’s Monopar Therapeutics MNPR Stock Holding History

JP Morgan Chase’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
2,506
+84
+3% +$5.2K ﹤0.01% 5531
2026
Q1 		$129K Buy
2,422
+313
+15% +$18.9K ﹤0.01% 5696
2025
Q4 		$138K Buy
2,109
+618
+41% +$50.5K ﹤0.01% 5722
2025
Q3 		$122K Sell
1,491
-430
-22% -$19.2K ﹤0.01% 5786
2025
Q2 		$68.7K Buy
1,921
+1,821
+1,821% +$66.1K ﹤0.01% 5774
2025
Q1 		$3.64K Sell
100
-1,937
-95% -$69.8K ﹤0.01% 6470
2024
Q4 		$44.8K Buy
+2,037
New +$34.2K ﹤0.01% 6055
2023
Q4 		– Sell
-1
Closed -$2 – 7738
2023
Q3 		$2 Buy
+1
New +$3 ﹤0.01% 7410
2023
Q2 		– Sell
-483
Closed -$3K – 7175
2023
Q1 		$3K Buy
+483
New +$7.15K ﹤0.01% 6347

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JP Morgan Chase's MNPR Position: Q2 2026 in Review

JP Morgan Chase increased its Monopar Therapeutics (MNPR) stake by 3.5% in Q2 2026, buying an estimated $5.2K and bringing the position to 2,506 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #5531.

JP Morgan Chase first reported a position in MNPR in Q1 2023 and has held it in 9 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • JP Morgan Chase held 2,506 shares of Monopar Therapeutics worth $237K as of Q2 2026.
  • JP Morgan Chase bought 84 Monopar Therapeutics shares in Q2 2026, an estimated $5.2K.
  • Monopar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5531 holding.
  • JP Morgan Chase first reported a position in Monopar Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.